Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) allo-SCT between 1999 and 2006. The purpose of this singlecenter study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m 2 at days À5 to À1) and CY (60 mg/kg at days À2, À1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.
Introduction
Conventional allo-SCT represents an accepted curative option for a variety of hematological malignancies and other disorders such as severe aplastic anemia, hemoglobinopathies and immunodeficiency disorders.
1,2 Nevertheless, these transplants are complicated by a relatively high treatment-related mortality (TRM) caused by toxicity of the myeloablative conditioning, GVHD and infections. 3 Therefore, this type of transplantation is generally limited to patients younger than 40-50 years of age with good health status. As the median age for many solid tumors and hematological malignancies is over 50 years, only a minority of patients may benefit from conventional allo-SCT.
In recent years, non-myeloablative or reduced-intensity (RIST) conditioning regimens have been developed, mostly consisting of purine analog (fludarabine) in combination with cytotoxic, immunosuppressive drugs or low-dose TBI. 4 Nowadays, this type of pretransplantation conditioning is used for both solid tumors and hematological malignancies, especially in patients of advanced age (455 years), with poor disease status, previous intensive treatment and refractory solid malignancies. Data from recent studies show a decreased TRM and/or less acute GVHD after RIST when compared with conventional myeloablative allo-SCT. [5] [6] [7] [8] In this paper, we describe the largest single-center experience with RIST allo-SCT in metastatic breast cancer (MBC). Fifteen subsequent patients with MBC underwent the RIST allo-SCT with a conditioning regimen consisting of fludarabine and CY with proven engraftment, also in solid tumors. 9 The presented data from one single center are supporting recently published promising data of the European Group for Blood and Marrow Transplant registry (EBMT) and MD Anderson Cancer Centre 10 and a recent review reporting relatively high response rates and supporting the role of allo-SCT for solid tumors.
11

Patients and methods
Patient eligibility
To be included in this phase II study, patients had to have a chemosensitive MBC, a (biological) age less than 65 years, minimal tumor load, HLA-identical sibling donor, measurable or evaluable disease, an expected life expectancy 43 months and informed consent was to be given. Exclusion criteria were pregnancy or lactation, active infections, other serious underlying condition, and concurrent treatment with other experimental agents.
Treatment schedule
Stem cells were obtained from HLA-identical related donors by leukapheresis after stimulation with filgrastim (10 mg/kg). The conditioning regimen consisted of fludar-abine 25 mg/m 2 at days À5, À4, À3, À2 and À1 and CY 60 mg/kg at days À2 and À1. Subsequently, all patients were transplanted with unmanipulated PBSCs. We aimed for at least 4 Â 10 6 /kg CD34-positive cells. Prophylaxis for GVHD consisted of standard CYA and standard MTX. 12 After relapse, progression or, in the case of incomplete chimerism at 30 days after transplantation (o80% donor cells), CYA was discontinued earlier. In case of no improvement after 1 month, patients were treated with donor lymphocyte infusions (DLI) 1 Â 10 7 CD3 þ cells/kg followed by, in case of no improvement, monthly increasing numbers of T lymphocytes (5 Â 10 7 CD3 þ cells/kg and 10 Â 10 7 CD3 þ cells/kg).
Evaluations and definitions
Diagnosis and clinical grading of acute and chronic GVHD were performed according to established criteria. 13, 14 Donor-host chimerism levels for sex-mismatched SCT were analyzed by FISH with probes specific for the X-and Y-chromosomes. For recipients of sex-matched SCT, chimerism was assessed using PCR-based amplification of STR polymorphism sequences unique to donors and hosts. TRM was defined as death if there was, at the time of death, no evidence of disease relapse or progression.
Supportive care
Infection prophylaxis, supportive care and follow-up were carried out according to standard local policy.
Objectives
The primary objective of this prospective study was whether RIST allo-SCT could produce a graft-vs-tumor effect in MBC, evidenced by tumor response after posttransplant immune manipulation, and improved PFS and OS. Other study end points were TRM and GVHD. Data were included till July 2008. PFS and OS were compiled using the Kaplan-Meier analysis. The number of patients to be included in this phase II study was 20; however, owing to slow accrual and changing oncology practices, the study was closed after the inclusion of 15 patients.
Results
Between March 1999 and October 2006, 15 patients with MBC, fulfilling the entry criteria, were treated with the RIST conditioning regimen followed by an allo-SCT using HLA-identical sibling donors. The basic characteristics of the patients are presented in Table 1 . The median age was 49.5 years (range 39.7-60.8 years). All patients had a WHO performance status 0-1 at admission for transplantation. The median time interval from the initial diagnosis of breast cancer till transplant was 6 years (range 0.6-20.3 years). All patients were extensively pretreated and all had undergone at least one palliative chemotherapy regimen for metastatic disease.
The median number of CD34 þ cells harvested from HLA-identical sibling donors by leukapheresis was 4.4 Â 10 6 CD34 þ cells/kg of the recipient (range 1.5-15.5).
All patients ultimately died: two out of 15 patients (13% TRM) died without proven tumor progression 138 and 144 days post transplant, respectively. These two patients died of infectious complications. All others died of disease progression. The median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively (see Figures 1 and 2) . The 1-year PFS was 20%, and the 1-, 2-and 3-year OS was 40, 20 and 13%, respectively.
The occurrence of acute GVHD was very low, and grades 1-2 and 3-4 were observed in one patient each (UPN 142 and 145) . Also, limited and extensive chronic GVHD occurred infrequently, each in one patient (UPN 142 and 145). These two patients had a PFS and OS close to the median.
Ten of the 15 (67%) patients received DLI: three patients once, two patients twice, three patients three times, and two patients four times. No objective tumor responses were observed. In one patient, a tumor marker decline was observed. After initial progression, she responded temporarily after DLI, as measured with CA 15-3 (see Figure 3 ).
Discussion
Here, we describe the results of a phase II study applying RIST allo-SCT in 15 MBC patients after a fludarabine and CY conditioning regimen. We conclude from this study that the TRM was relatively low (13%), the GVHD limited, and that no objective tumor response was observed other than a temporary CA 15-3 response after DLI. To interpret our data more carefully, comparative data should be available, which is not the case in this phase II study. However, the absence of major responses and only one temporary tumor marker CA 15-3 decline after DLI suggests that the antitumor effect in this group of patients with MBC is limited. Also, patients with acute or chronic GVHD did not appear to fare better.
Previous publications, with generally smaller numbers than this study, were mainly single-center studies with more or less promising results. Carella et al. 15 reported an overall response rate of 24%, after a tandem approach, consisting of high-dose chemotherapy with auto-SCT to achieve maximum tumor reduction before proceeding to allo-SCT. Bishop et al. 16 observed that objective tumor regressions in 33% of the patients were attributable to allogeneic lymphocyte infusions. Ueno et al.
17 treated 10 patients with MBC observing two CRs and one minimal response. Bregni et al. 18 observed a PR in two (33%) patients.
Recently, an overview of international collaboration was published. 10, 11 In these studies, response rates attributable to a graft-vs-tumor effect were 16-37%, leading to the conclusion that a graft-vs-tumor effect exists in MBC. Ueno et al. 17 reported that in a myeloablative conditioning regimen, the development of acute GVHD was associated with an increased risk of treatment failure (progression, relapse or death). However, in women treated with RIST, there was a decreased risk of treatment failure associated with the development of acute GVHD. In his report, the cumulative incidence of grades II-IV acute GVHD at 100 days was 44% after myeloablative conditioning and 34% after RIST. The cumulative incidence of chronic GVHD at 1 year was much higher in the myeloablative group (36%) than in the RIST group (8%). 10 In MBC, the median PFS and OS with second-line and higher lines of chemotherapy are in the range of 3-4 and 8-12 months, respectively. 19 In our heavily pretreated group, the median PFS was almost 5 months, which, despite the absence of an objective tumor response, does suggest a graft-vs-tumor effect.
We conclude that the routine application of nonmyeloablative transplantation for MBC may lead to a small benefit in PFS.
The antitumor effect after allo-SCT relies more or less on a T-cell effect. We feel that this effect is limited. We cannot exclude that a different approach exploiting a natural killer-cell effect, as in haploidentical transplants, would result in a better outcome. 18, 20 Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer. -61  90  110  152  176  201  229  285  362  508  575  705  754  818  873  901  957  1008  600  649  397 460 320 Figure 3 One patient (UNP 101) with metastatic breast cancer, progressing after reduced intensity transplantation, with a temporary tumor marker response to increasing doses of donor lymphocyte infusions.
